Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: Studies in humans and in a mouse model of diabetes

Diabetologia

Volumn 56, Issue 5, 2013, Pages 1155-1165

  Watson, A M D ^a   Olukman, M ^a   Koulis, C ^a   Tu, Y ^a   Samijono, D ^a   Yuen, D ^a   Lee, C ^a   Behm, D J ^b   Cooper, M E ^a,c   Jandeleit Dahm, K A M ^a,c   Calkin, A C ^a   Allen, T J ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b GLAXOSMITHKLINE   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Animal model; Atherosclerosis; Diabetes mellitus; Endothelial cells; Macrovascular disease; Mouse

Indexed keywords

2 BROMO N [4 CHLORO 3 [(1 METHYL 3 PYRROLIDINYL)OXY]PHENYL] 4,5 DIMETHOXYBENZENESULFONAMIDE; 3 NITROTYROSINE; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; UROTENSIN RECEPTOR; UROTENSIN RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CELL ADHESION; CONTROLLED STUDY; CULTURE MEDIUM; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG ANTAGONISM; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HYPERGLYCEMIA; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; UPREGULATION;

ANIMALS; AORTA; ATHEROSCLEROSIS; CELL ADHESION; CELLS, CULTURED; CROSSES, GENETIC; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; PILOT PROJECTS; PROTECTIVE AGENTS; RECEPTORS, G-PROTEIN-COUPLED; SULFONAMIDES; UROTENSINS;

EID: 84876499285     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2837-9     Document Type: Article

References (39)

1. Pearson D, Shively JE, Clark BR, et al.(1980) Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77:5021-5024
2. Ames RS, Sarau HM, Chambers JK, et al.(1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401:282-286
3. Liu Q, Pong SS, Zeng Z, et al.(1999) Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266:174-178
4. Mori M, Sugo T, Abe M, et al.(1999) Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 265:123-129
5. Nothacker HP, Wang Z, McNeill AM, et al.(1999) Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1:383-385
6. Tal M, Ammar DA, Karpuj M, Krizhanovsky V, Naim M, Thompson DA (1995) A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem Biophys Res Commun 209:752-759
7. Douglas SA, Dhanak D, Johns DG (2004) From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25:76-85
8. Onan D, Hannan RD, Thomas WG (2004) Urotensin II: the old kid in town. Trends Endocrinol Metab 15:175-182
9. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP (2004) Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25:1767-1774
10. Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A (2004) Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176:117-123
11. Papadopoulos P, Bousette N, Al-Ramli W, et al.(2009) Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: Effect of UT antagonism in Apoe knockout mice fed with Western diet. Atherosclerosis 204:395-404
12. Watanabe T, Suguro T, Kanome T, et al.(2005) Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46:738-744
13. Shiraishi Y, Watanabe T, Suguro T, et al.(2008) Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. J Hypertens 26:1955-1965
14. Clozel M, Hess P, Qiu C, Ding SS, Rey M (2006) The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 316:1115-1121
15. Vogt L, Chiurchiu C, Chadha-Boreham H, et al.(2010) Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. Hypertension 55:1206-1209
16. Douglas SA, Behm DJ, Aiyar NV, et al.(2005) Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br J Pharmacol 145:620-635
17. Krege JH, Hodgin JB, Hagaman JR, Smithies O (1995) A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25:1111-1115
18. Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD, Izlar C (1994) Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin Chem 40:1317-1321
19. Watson AMD, Li J, Schumacher C, et al.(2010) The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 53:192-203
20. Soro-Paavonen A, Watson AMD, Li J, et al.(2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57:2461-2469
21. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O (2003) Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 104:1-5
22. Suguro T, Watanabe T, Kodate S, et al.(2008) Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in type 2 diabetes mellitus. Clin Sci (Lond) 115:327-334
23. Wang HX, Zeng XJ, Liu Y, et al.(2009) Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse. Regul Pept 154:89-90
24. Cirillo P, de Rosa S, Pacileo M, et al.(2008) Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. J Thromb Haemost 6:726-736
25. Ishihata A, Ogaki T, Aita T, Katano Y (2005) Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol 523:119-126
26. Szerafin T, Erdei N, Fulop T, et al.(2006) Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ Res 99:e12-e17
27. Cipollone F, Prontera C, Pini B, et al.(2001) Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104:921-927
28. Lewis P, Stefanovic N, Pete J, et al.(2007) Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 115:2178-2187
29. Diebold I, Petry A, Burger M, Hess J, Gorlach A (2011) NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II. Mol Biol Cell 22:4424-4434
30. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A (2005) Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25:519-525
31. Schaffer SW, Jong CJ, Mozaffari M (2012) Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited. Vasc Pharmacol 57:139-149
32. Golbidi S, Ebadi SA, Laher I (2011) Antioxidants in the treatment of diabetes. Curr Diabetes Rev 7:106-125
33. Bousette N, D'Orleans-Juste P, Kiss RS, et al.(2009) Urotensin II receptor knockout mice on an Apoe knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype. Circ Res 105:686-695
34. Maguire JJ, Kuc RE, Kleinz MJ, Davenport AP (2008) Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function. Peptides 29:735-742
35. Katugampola SD, Kuc RE, Maguire JJ, Davenport AP (2002) G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. Clin Sci (Lond) 103(Suppl 48):171S-175S
36. Watson AMD, Lambert GW, Smith KJ, May CN (2003) Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42:373-379
37. Guidolin D, Albertin G, Oselladore B, et al.(2010) The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways. Regul Pept 162:26-32
38. Shi L, Ding W, Li D, et al.(2006) Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 188:260-264
39. Mas S, Martinez-Pinna R, Martin-Ventura JL, et al.(2010) Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes. Diabetes 59:1292-1301